We use the published mean weight loss at trial endpoint for each medication and dose, then apply an S-curve (logistic) interpolation to estimate weekly progress. The curve assumes early plateaus from titration and gradual deceleration as you approach the asymptote.
- Wegovy 2.4 mg: 14.9% mean loss at 68 weeks (STEP-1).
- Mounjaro / Zepbound 15 mg: 22.5% at 72 weeks (SURMOUNT-1).
- Mounjaro / Zepbound 10 mg: 19.5% at 72 weeks.
- Mounjaro / Zepbound 5 mg: 15.0% at 72 weeks.
- Ozempic 2.0 mg: ~6.9% at 40 weeks (SUSTAIN FORTE — note: type 2 diabetes population, lower loss than non-diabetic).
- Saxenda 3.0 mg: 8.0% at 56 weeks (SCALE).
- Rybelsus 14 mg: 4–6% at 26 weeks (PIONEER trials).
Goal reach date is the earliest projected week when modeled weight crosses your goal weight. If your goal exceeds the medication's typical efficacy ceiling, we display "Goal beyond typical range."